Abstract
Mdm2 is a well studied oncogene and has been reported to be closely related to chemoresistance in different manners. In this article, we discuss the current knowledge of mdm2’s function in drug resistance, the novel relationship between MDM2 and Akt phosphorylation, the role of Akt signaling pathway in epithelial-mesenchymal transition, and the positive correlation among MDM2, epithelial-mesenchymal transition and drug resistance. We propose a possible pathway by which MDM2 increases drug resistance through inducing epithelial-mesenchymal transition independent of p53. This pathway may play a significant role in the tumorigenesis and chemoresistance. By targeting MDM2, we can re-activate the function of p53, inhibit the epithelial-mesenchymal transition process and thus increase cancer cells sensitivity to chemotherapy. Thus, from p53-dependent and p53-independent aspects, it may present a better strategy for cancer treatment than targeting other genes.
Keywords: Mdm2, Akt phosphorylation, p53, drug resistance, epithelial-mesenchymal transition.
Current Medicinal Chemistry
Title:MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Volume: 23 Issue: 40
Author(s): Weichao Sun and Liling Tang
Affiliation:
Keywords: Mdm2, Akt phosphorylation, p53, drug resistance, epithelial-mesenchymal transition.
Abstract: Mdm2 is a well studied oncogene and has been reported to be closely related to chemoresistance in different manners. In this article, we discuss the current knowledge of mdm2’s function in drug resistance, the novel relationship between MDM2 and Akt phosphorylation, the role of Akt signaling pathway in epithelial-mesenchymal transition, and the positive correlation among MDM2, epithelial-mesenchymal transition and drug resistance. We propose a possible pathway by which MDM2 increases drug resistance through inducing epithelial-mesenchymal transition independent of p53. This pathway may play a significant role in the tumorigenesis and chemoresistance. By targeting MDM2, we can re-activate the function of p53, inhibit the epithelial-mesenchymal transition process and thus increase cancer cells sensitivity to chemotherapy. Thus, from p53-dependent and p53-independent aspects, it may present a better strategy for cancer treatment than targeting other genes.
Export Options
About this article
Cite this article as:
Sun Weichao and Tang Liling, MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53, Current Medicinal Chemistry 2016; 23 (40) . https://dx.doi.org/10.2174/0929867323666160926150820
DOI https://dx.doi.org/10.2174/0929867323666160926150820 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Biomarkers for Bladder Cancer Diagnosis and Surveillance
Mini-Reviews in Medicinal Chemistry Potential Utility of Mycobacterium w Vaccine in Control of Tuberculosis
Current Respiratory Medicine Reviews New Approaches to Photodynamic Therapy from Types I, II and III to Type IV Using One or More Photons
Anti-Cancer Agents in Medicinal Chemistry Emerging Potential of Natural Products as an Alternative Strategy to Pharmacological Agents Used Against Metabolic Disorders
Current Drug Metabolism Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Specialisation of the Tropomyosin Composition of Actin Filaments Provides New Potential Targets for Chemotherapy
Current Cancer Drug Targets Targeting Prostate Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Bioactive Cyclohexenones: A Mini Review
Current Bioactive Compounds Targeting Heme for the Identification of Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Molecular Tools in Cancer Diagnosis and Therapy Guest Editor: Riyaz Basha]
Current Medicinal Chemistry PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Role of Vitamins in Human Health and Nutrition: Sources and Morbidity
Current Nutrition & Food Science Overview of Cantharidin and its Analogues
Current Medicinal Chemistry The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Current Trends and Future Directions of Fluoroquinolones
Current Medicinal Chemistry Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued)